Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008

Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00982514

Enrollment

Registered

2009-09-23

Start date

2009-09-30

Completion date

2014-12-31

Last updated

2012-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia, Thromboembolism

Keywords

Asparaginase, thrombosis, ALL, central line

Brief summary

The study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will prospectively study clinical symptomatic thromboses, asymptomatic central line-associated thromboses, and infections.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 16 Years

Healthy volunteers

Inclusion criteria

* Acute lymphoblastic leukaemia, * Age 1 year to 16 years old, * Central line, * Protocol NOPHO ALL 2008.

Exclusion criteria

* Refusal of participation, * Treated according to protocol other than NOPHO ALL 2008.

Design outcomes

Primary

Measure	Time frame
Clinical evident thrombosis	33 weeks
Asymptomatic central line-associated thrombosis	33 weeks

Secondary

Measure	Time frame
Positive blood culture	33 weeks

Countries

Norway

Contacts

Primary ContactEllen Ruud, MD PhD

ellen.ruud@rikshospitalet.no+47 23074560

Backup ContactTonje Reiersen, MD

tonje.reiersen@rikshospitalet.no+47 23070000

Outcome results